Plural Oxygens Bonded Directly To The Same Sulfur (e.g., Sulfones, Etc.) Patents (Class 514/709)
-
Patent number: 8178580Abstract: Methods, formulations, and compositions for the treatment of amyloidosis are described.Type: GrantFiled: April 17, 2006Date of Patent: May 15, 2012Assignee: Kiacta SarlInventors: Denis Garceau, Wendy Hauck, Richard Briand
-
Patent number: 8158575Abstract: Use of a polylysine, polyamidoamine or polypropylenimine dendrimer having naphthyl disulphonate terminal groups as a topically applied agent in prophylaxis or treatment of sexually transmitted diseases.Type: GrantFiled: July 6, 2009Date of Patent: April 17, 2012Assignee: Starpharma Pty., LtdInventors: Barry Ross Matthews, George Holan, Peter Karellas, Scott Andrew Henderson, David Francis O'Keefe
-
Publication number: 20120083536Abstract: An adhesive composition having dispersed therein a broad spectrum antimicrobial agent for use in medical applications, such as an adhesive for surgical drapes, wound dressings and tapes, is provided. The adhesive is composed of acrylic polymers, tackifiers and a preferred antimicrobial agent, diiodomethyl-p-tolylsulfone. The subject adhesive composition may be formulated as either an essentially solventless hot melt, or as a solvent based system wherein an emulsion of the antimicrobial agent and the removal of excess solvent is avoided.Type: ApplicationFiled: September 30, 2011Publication date: April 5, 2012Inventors: David D. Cox, Robert E. Lund, Leland W. Annett
-
Patent number: 8148348Abstract: Provided are a process for producing a S-adenosyl-L-methionine-containing composition which is very excellent in a stability by adding at least ascorbic acids or salts thereof to a composition liquid containing S-adenosyl-L-methionine and then drying the above composition liquid or separating and drying a crystallized deposit obtained from the above composition liquid, a S-adenosyl-L-methionine-containing composition obtained by the above production process and a molding obtained from the above composition.Type: GrantFiled: January 16, 2007Date of Patent: April 3, 2012Assignee: Mitsubishi Gas Chemical Company, Inc.Inventors: Kentarou Takano, Shinyo Gayama
-
Publication number: 20120045496Abstract: A composition for treating fabric includes about 0.1 to about 10.0% cross linking agent, about 0.1 to about 5.0% of a material selected from a group consisting of oxidized polyolefin, polyolefin and mixtures thereof, about 0.1 to about 0.5% wetting agent, about 1.0 to about 14.0% of a material selected from a group consisting of aminofunctional silicone, ionizing agent and mixtures thereof, about 0.0 to about 2.0% catalyst, about 1.0 to about 3.0% antimicrobial/antibacterial/antifungal agent and any remainder as a carrier. The composition has a pH of between about 2.0 to about 4.0. A performance fabric treated with the composition and a method of treating a performance fabric are also provided.Type: ApplicationFiled: February 12, 2009Publication date: February 23, 2012Inventors: Dan C. Short, Bryan S. Short, Albert B. Quimet
-
Publication number: 20120034176Abstract: The present invention relates to a compound of the general formula (I) where: X?S, SO or SO2; and one of the radicals R1 and R2 is a hydrogen atom and the other is a radical: a C1 to C18 linear or branched alkyl, optionally substituted by one or more halogen atom(s); a C2 to C18 linear or branched alkenyl, optionally substituted by one or more halogen atom(s); an aralkyl, optionally substituted by one or more C1 to C6alkoxy group(s); or a COR3 or CONHR3, but not simultaneously, where R3 is a radical: a C1 to C18 linear or branched alkyl, optionally substituted by one or more halogen atom(s); a C2 to C18 linear or branched alkenyl, optionally substituted by one or more halogen atom(s); an aralkyl, optionally substituted by one or more C1 to C6alkoxy group(s); an aralkenyl, optionally substituted by one or more C1 to C6 alkoxy groups and/or one or more OH group(s); or an aryl radical, optionally substituted by one or more C1 to C6 alkoxy group(s).Type: ApplicationFiled: April 8, 2010Publication date: February 9, 2012Applicant: PIERRE FABRE DERMO-COSMETIQUEInventor: Stéphane Poigny
-
Patent number: 8110608Abstract: A pesticide composition and method of eliminating pests combines water and a solid form of sodium lauryl sulfate to form a pesticide composition effective to cause mortality in pests. The pesticide composition is applied to the indoor structure in an area which the pests inhabit. The sodium lauryl sulfate can be in needle form, pellet form or powder form and constitutes between about 1% and about 10% by weight of the pesticide composition. The pesticide composition may be applied to an area inhabited by cockroaches, including, but not limited to, in crevices, cracks, corners, wall and floor junctures or other enclosed or partially enclosed areas of a structure.Type: GrantFiled: June 3, 2009Date of Patent: February 7, 2012Assignee: Ecolab USA Inc.Inventors: Kelly Herrera, Stephen John Barcay
-
Patent number: 8106033Abstract: Methods and compositions are provided for treating proliferative disorders, wherein the composition comprises at least one compound according to Formula I: wherein R1 is selected from the group consisting of —OH, —NH2, —NH—CH2—CO2H, —NH—CH(CH3)—CO2H, and —NH—C(CH3)2—CO2H, or a pharmaceutically acceptable salt of such a compound; and an anthracycline, e.g. doxorubicin, or a pharmaceutically acceptable salt thereof, or a platin, e.g. oxaliplatin, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 10, 2006Date of Patent: January 31, 2012Assignees: Temple University - Of The Commonwealth System of Higher Education, Mount Sinai School of MedicineInventors: E. Premkumar Reddy, James F. Holland
-
Patent number: 8101660Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.Type: GrantFiled: August 15, 2007Date of Patent: January 24, 2012Assignee: AmDerma Pharmaceuticals, LLCInventors: Pedro Cuevas Sánchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Morgan, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Patent number: 8058313Abstract: ?,?-Unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides of Formula I: wherein R1, R2, M1, M2, L, E1, E2, Q1, Q2 and n are as defined herein, are useful as anti-angiogenesis agents, as agents for treatment of age related senile dementia, and as antiproliferative agents including, for example, as anticancer agents.Type: GrantFiled: June 23, 2005Date of Patent: November 15, 2011Assignee: Temple University—Of The Commonwealth System of Higher EducationInventors: E. Premkumar Reddy, M. V. Ramana Reddy
-
Patent number: 7998462Abstract: An improved linker which lacks chiral centers between a hydrophobic anchor for coupling to lipid-based particles and a targeting agent has suitable hydrophobic/hydrophilic properties for use in vivo.Type: GrantFiled: October 16, 2007Date of Patent: August 16, 2011Assignee: Kereos, Inc.Inventor: William D. McGhee
-
Publication number: 20110190400Abstract: The present invention comprises compounds, compositions and methods of use for sensitizing cancer cells, tumors, neoplasms, and malignancies to the effects of ionizing radiation used in the treatment of cancer. The invention further comprises a method of identifying novel radiosensitizing compounds.Type: ApplicationFiled: September 12, 2008Publication date: August 4, 2011Applicant: The Trustees of the University of PennsylvaniaInventors: Constantinos Koumenis, Brian E. Lally, Steven Kridel, Gary D. Kao, Adeboye Adejare
-
Patent number: 7932242Abstract: Substituted phenol derivatives of Formula (I) are useful as antiproliferative agents including, for example, anticancer agents, and as radioprotective and chemoprotective agents.Type: GrantFiled: March 15, 2005Date of Patent: April 26, 2011Assignees: Temple University - Of The Commonwealth System of Higher Education, Onconova Therapeutics Inc.Inventors: E. Premkumar Reddy, M. V. Ramana Reddy, Stanley C. Bell
-
Publication number: 20110039874Abstract: Disclosed are compounds and compositions that inhibit the action of monoacylglycerol lipase (MGL) and fatty acid amide hydrolase (FAAH), methods of inhibiting MGL and FAAH, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors.Type: ApplicationFiled: April 16, 2010Publication date: February 17, 2011Applicant: Northeastern UniversityInventors: Alexandros Makriyannis, Spyridon P. Nikas, Shakiru O. Alapafuja, Vidyanand G. Shukla
-
Publication number: 20100323037Abstract: A composition that includes ethylhexyl sulfate or a salt thereof, an alkylbenzenesulfonic acid or a salt thereof, and a carrier. The ethylhexyl sulfate, or salt thereof, and the alkylbenzenesulfonic acid, or salt thereof, are present in a weight ratio of at least about 1:2. The composition can be used for killing or inhibiting a microorganism or pathogen (e.g., bacteria, gram-negative bacteria, gram-positive bacteria, enteric bacteria, virus, fungus, mold, mildew or powdery mildew).Type: ApplicationFiled: June 22, 2009Publication date: December 23, 2010Applicant: EQ Ag SolutionsInventors: Patrick J. Curry, Franklin Irven Diehl
-
Publication number: 20100311756Abstract: The present invention relates to methods for reducing the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular dysfunction following a cardiac insult in a subject in need of treatment thereof. Moreover, the present invention also relates to methods of delaying the onset of heart failure symptoms or reducing the incidence of cardiovascular events following a cardiac insult in a subject in need of treatment thereof.Type: ApplicationFiled: January 19, 2010Publication date: December 9, 2010Applicant: TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.Inventors: Lin Zhao, Robert Hamlin, Yingjie Chen
-
Patent number: 7842836Abstract: This invention concerns N-(ortho phenylaminoaryl), N?-alkyl sulfamides which are inhibitors of MEK and are useful in the treatment of cancer and other hyperproliferative diseases.Type: GrantFiled: April 11, 2007Date of Patent: November 30, 2010Assignee: Ardea BiosciencesInventors: Shunqi Yan, Jean-Michel Vernier, Zhi Hong
-
Publication number: 20100267801Abstract: Sulphones of formula (I) are disclosed for use in treatment of cancer.Type: ApplicationFiled: May 16, 2006Publication date: October 21, 2010Inventors: Huw David Lewis, Timothy Harrison, Mark Steven Shearman
-
Publication number: 20100261674Abstract: Fatty acid amide hydrolase (FAAH) is an enzyme responsible for the degradation of oleamide (an endogenous sleep-inducing lipid) and anandamide (an endogenous ligand for cannabinoid receptors). Disclosed herein are potent inhibitors of FAAH and methods for their use for treating a variety of disorder, including hypertension and cardiac hypertrophy.Type: ApplicationFiled: April 6, 2010Publication date: October 14, 2010Inventors: George Kunos, Alexandros Makriyannis
-
Patent number: 7803407Abstract: A non-toxic environmentally friendly aqueous disinfectant is disclosed for specific use as prevention against contamination by potentially pathogenic bacteria and virus. The aqueous disinfectant is formulated by electrolytically generating silver ions in water in combination with a citric acid. The aqueous disinfectant may include a suitable alcohol and/or a detergent. The aqueous disinfectant has been shown to be very effective at eliminating standard indicator organisms such as staphylococcus aureus, salmonella cholerasuis and pseudomonas aeruginosa.Type: GrantFiled: June 19, 2003Date of Patent: September 28, 2010Assignee: Pure BioscienceInventor: Andrew B. Arata
-
Publication number: 20100234379Abstract: The endocannabinoid transporter and FAAH are sites of modulation that allow pharmacological enhancement of protective endocannabinergic signals. Selective inhibitors of the transporter and inhibitors of FAAH caused additive augmentation of endogenous signaling events mediated by the cannabinoid CB1 receptor. Disruption of such signals has been shown to prevent neuronal maintenance processes and increase vulnerability to brain damage. Here, blocking endocannabinoid inactivation enhanced cannabinergic activity and ameliorated cellular disturbances associated with excitotoxicity. Modulating the endocannabinoid system in this way also prevented excitotoxic behavioral abnormalities including memory impairment. Collectively, these results indicate that increasing endocannabinoid responses by inhibiting the endocannabinoid transported and/or the inhibiting FAAH leads to molecular, cellular, and functional protection against excitotoxic insults like stroke and traumatic brain injury.Type: ApplicationFiled: July 28, 2006Publication date: September 16, 2010Inventors: Ben A. Bahr, Alexandros Makriyannis, David A. Karanian
-
Publication number: 20100234328Abstract: A liquid antimicrobial composition comprising an organic acid and one or more anionic surfactants is disclosed. In one embodiment, the organic acid is lactic acid and the anionic surfactant is sodium octane sulfonate. In a preferred embodiment, the antimicrobial solution is formulated as a teat dip for lactating animals, particularly cows. In other embodiments, the antimicrobial compositions may be used in personal care, hard surface care including hard surface disinfection in households, food processing, hospitals, restaurants, hotels, showers, or topically as hand soaps, surgical scrubs, and hoof disease mitigators.Type: ApplicationFiled: September 10, 2007Publication date: September 16, 2010Applicant: DELAVAL HOLDINGS ABInventors: Fahim U. Ahmed, Alex Skender, Thomas C. Hemling, Camelia N. Traistaru
-
Publication number: 20100227937Abstract: An adhesive composition having dispersed therein a broad spectrum antimicrobial agent for use in medical applications, such as an adhesive for surgical drapes, wound dressings and tapes, is provided. The adhesive is composed of acrylic polymers, tackifiers and a preferred antimicrobial agent, diiodomethyl-p-tolylsulfone. The subject adhesive composition may be formulated as either an essentially solventless hot melt, or as a solvent based system wherein an emulsion of the antimicrobial agent and the removal of excess solvent is avoided.Type: ApplicationFiled: February 26, 2010Publication date: September 9, 2010Inventors: David D. Cox, Robert E. Lund, Leland W. Annett
-
Patent number: 7790771Abstract: The invention concerns the use of tosylchloramide(s), tosylchloramide salt(s), their derivatives and/or the decomposition products for treating diseases of the skin, mucous membranes, organs and tissues, excluding treatment of retroviral diseases (HIV) and disinfecting processes. It has been shown that tosylchloramide compounds can be used even for all diseases of the skin and viral mucosa causing formation of vesicles and itching, and they can lead to similar results as those obtained when they are used to treat corresponding diseases in tissues and organs. They not only provide quick relief of the acute symptoms and cure, but they also reduce frequency of recurrence. The inventive use is characterised in that it leads to very good treatment results, entirely independently of the form of preparation used, and it does not have to be administered in one specific manner. Relatively low amounts of tosylchloramide active principle can provide complete cure.Type: GrantFiled: July 21, 2000Date of Patent: September 7, 2010Assignee: Engelhard Arzneimittel GmbH & Co.Inventors: Horst Rapp, Friedbert Heck
-
Patent number: 7772156Abstract: Microbicidal compositions including (a) cyanodithiocarbimate and (b) an N-alkyl heterocyclic compound; a triazole compound or salt thereof or metal complex thereof; a microbicide with an activated halogen atom or a formaldehyde releasing compound; 1,4-bis(bromoacetoxy)-2-butene; 2-(thiocyanomethylthio)benzothiazole; a methylene-bis(thiocyanate); a halogenated acetophenone; a halopropynl compound; an iodosulfone; a phenol; a halocyanoacetamide compound and/or a quaternary ammonium compound are described. Components (a) and (b) can be present in a synergistically effective amount to control the growth of at least one microorganism. Methods for controlling the growth of microorganisms with the compositions are also disclosed.Type: GrantFiled: November 1, 2006Date of Patent: August 10, 2010Assignee: Buckman Laboratories International, Inc.Inventor: Stephen D. Bryant
-
Patent number: 7763662Abstract: Embodiments of the invention relate to methods of reducing weight in mammals and for the prophylaxis or treatment of obesity comprising administration of C2-substituted indan-1-ol systems and their physiologically acceptable salts and physiologically functional derivatives. Compounds for use in the methods of the embodiments of the invention include compounds of the formula (I) in which the radicals are as defined, and their physiologically acceptable salts.Type: GrantFiled: December 7, 2004Date of Patent: July 27, 2010Assignee: Sanofi-Aventis Deutschland GmbHInventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
-
Publication number: 20100160422Abstract: There is provided a halogen-containing organosulfur compound having an excellent controlling effect on arthropod pests represented by the formula (I): wherein, m represents 0, 1 or 2, n represents 0, 1 or 2, A represents optionally substituted C3-C7 cycloalkyl or optionally substituted C5-C7 cycloalkenyl group, Q represents a C1-C5 haloalkyl group containing at least one fluorine atom, or a fluorine atom, R1 and R3 independently represent optionally substituted C1-C4 chain hydrocarbon, halogen or hydrogen, R2 and R4 independently represent optionally substituted C1-C4 chain hydrocarbon, —C?C(=G)R5, cyano, halogen or hydrogen, G represents oxygen or sulfur, and R represents optionally substituted C1-C4 alkyl, hydroxyl, optionally substituted C1-C4 alkoxy, optionally substituted C3-C6 alkenyloxy, optionally substituted C3-C6 alkynyloxy, amino, optionally substituted C1-C4 alkylamino, optionally substituted di(C1-C4 alkyl)amino, C2-C5 cyclic amino or hydrogen.Type: ApplicationFiled: June 26, 2008Publication date: June 24, 2010Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventor: Hiromasa Mitsudera
-
Publication number: 20100144890Abstract: Use of a mixture comprising at least one non-aromatic surfactant having a plurality of ether and/or ester groups and at least one carrier agent for the preparation of a formulation for the treatment of adipose tissue disease and/or condition with improved bioavailability and lipolysis behaviour.Type: ApplicationFiled: January 14, 2008Publication date: June 10, 2010Inventors: Peter Boderke, Bernhard Hauptmeier, Edgar Mentrup, Holger Kohler, Rainer Pooth
-
Publication number: 20100144867Abstract: The present invention relates to a method of evaluating the cancer state of a subject using lecithin:retinol acyl transferase (LRAT) gene promoter methylation status. Methods of analyzing and quantifying LRAT gene promoter methylation level are also disclosed. The present invention also relates to methods of determining the prognosis for s subject having cancer by assessing LRAT mRNA expression and LRAT protein expression. Methods of cancer detection, diagnosis, prognosis, and treatment are also disclosed.Type: ApplicationFiled: December 19, 2007Publication date: June 10, 2010Applicants: CORNELL RESEARCH FOUNDATION, INC., SLOAN KETTERING CANCER CENTER, UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Francis Barany, Yu-Wei Cheng, Philip Paty, Daniel Notterman
-
Patent number: 7713954Abstract: Methods and pharmaceutical compositions relating to selective antagonists of the 5-HT6 receptor and 5-HT2A receptor useful for the treatment of cognitive disorders are presented.Type: GrantFiled: September 30, 2005Date of Patent: May 11, 2010Assignee: Roche Palo Alto LLCInventors: Douglas William Bonhaus, Renee Sharon Martin
-
Publication number: 20100080843Abstract: The present invention relates to inhibiting angiogenesis with sulfur- or selenium-containing compounds, and polymeric forms thereof, in mammals including animals and humans. Sulfur- or selenium-containing compounds, and polymeric forms thereof, can be used alone or in combination with standard therapies to inhibit angiogenesis-mediated disorders. The present invention also relates to the combined use of sulfur- or selenium-containing compounds, and polymeric forms thereof, with other anti-angiogenesis agents, with various anti-inflammatory and cytotoxic agents as well as with radio-therapeutic agents in cancer, and with laser, photodynamic therapy for ocular-related disorders such as diabetic retinopathy or age-related macular degeneration.Type: ApplicationFiled: June 30, 2006Publication date: April 1, 2010Applicant: The Research Foundation of the State University Of New York at AlbanyInventors: Shaker Mousa, Eric Block
-
Patent number: 7687076Abstract: A method for producing a deposition product includes providing a deposition solution having a pH below 7 and comprising an aqueous solution of a silver salt comprised of silver ions and an oxidizing agent. The silver salt is comprised of silver nitrate and has a concentration in the deposition solution between about 1 and 20 grams per liter. The oxidizing agent is comprised of a persulfate and has a concentration in the deposition solution between about 1 and 50 grams per liter. The method further includes producing the deposition product by facilitating a chemical reaction between the silver ions and the oxidizing agent while maintaining the deposition solution at a temperature of between about 2 and 40 degrees Celsius. The deposition product consists essentially of at least one oxidized silver species, and is comprised of a compound having the formula Ag7O8X, where X is an anion.Type: GrantFiled: November 2, 2007Date of Patent: March 30, 2010Assignee: Exciton Technologies Inc.Inventor: Stojan Djokic
-
Publication number: 20100047349Abstract: A stabilized solid preparation having stabilized drug content and stabilized appearance, comprising a main ingredient layer and a coating layer formed on the main ingredient layer, wherein the main ingredient layer comprises a granule or a fine particle comprising a substance capable of being unstabilized when losing water of crystallization and a water-soluble polymer and the coating layer comprises a water-soluble polymer and a sugar.Type: ApplicationFiled: June 22, 2007Publication date: February 25, 2010Applicant: Takeda Pharmaceutical Company LimitedInventors: Shinji Ohmori, Midori Matsuoka
-
Publication number: 20100048713Abstract: The invention relates to new chemical compounds acting on the serotonin transporter (SERT), and associated pharmaceutical compositions, methods for use as therapeutic agents, and methods of preparation thereof. In particular the new chemical compounds are useful for the treatment of a variety of central nervous system (CNS) disorders—for example anxiety, depression, epilepsy, obsessive-compulsive disorders, migraine, cognitive disorders, sleep disorders, feeding disorders, panic attacks, disorders related to withdrawl from drug abuse, schizophrenia, or the like, or in the treatment of gastrointestinal disorders such as irritable bowel syndrome.Type: ApplicationFiled: January 8, 2007Publication date: February 25, 2010Applicants: Aarhus Universitet, Region MidtjyllandInventors: Ove Kjaer Wiborg, Henrik Amtoft Neubauer
-
Patent number: 7659426Abstract: The present invention provides a pharmaceutical composition containing, as an active ingredient, a compound that specifically binds to KSRP or a functional fragment thereof, and a screening method for the compound. KSRP is a novel target protein for anticancer agents; a compound capable of regulating the expression and activity of such a protein and a pharmaceutical composition containing it are highly useful for proliferative diseases, particularly as anticancer agents. By providing the novel target protein, the mechanism behind the anticancer effect that has conventionally been unexplainable can be elucidated.Type: GrantFiled: November 30, 2004Date of Patent: February 9, 2010Assignee: Reverse Proteomics Research Institute Co., Ltd.Inventors: Akito Tanaka, Akira Yamazaki, Takeshi Tsutsumi, Tomohiro Terada, Masayuki Haramura
-
Patent number: 7655681Abstract: A method of treating or preventing Obstructive Sleep Apnea (OSA) comprises the administration of a pharmacologically effective amount of zonisamide to a patient in need thereof, with the proviso that OSA caused by external mechanical obstruction of the airways, such as by mucus, is excluded. Also disclosed is the use of zonisamide for the manufacture of a medicament useful in the treatment; a protective patch comprising zonisamide and a pharmaceutically acceptable carrier for transdermal or transmucosal administration to a person suffering from OSA; and the use of zonisamide for the manufacture of a diagnostic device, kit or composition for the diagnosis of sleep disordered breathing.Type: GrantFiled: February 15, 2005Date of Patent: February 2, 2010Inventors: Ludger Grote, Kaj Stenlof, Jan Hedner
-
Patent number: 7645752Abstract: The present invention is directed to compounds of Formula I: which are modulators of the 5-hydroxtryptamine-6 and 5-hydroxytryptamine-2A receptors and which are inhibitors of norepinephrine reuptake. The compounds of the invention, and pharmaceutical composition thereof, are useful in the treatment of disorders related to or associated with the 5-hydroxytryptamine-6 and 5-hydroxtryptamine-2A receptors or with norepinephrine reuptake inhibition.Type: GrantFiled: January 12, 2007Date of Patent: January 12, 2010Assignee: Wyeth LLCInventors: Robert E. McDevitt, Yanfang Li, Albert J. Robichaud, Gavin D. Heffernan, Richard D. Coghlan, Ronald C. Bernotas
-
Patent number: 7642272Abstract: There are disclosed compounds of the formula I a pharmaceutically acceptable salt or solvate of the compound, which exhibit anti-inflammatory and immunomodulatory activity. Also disclosed are pharmaceutical compositions containing said compounds.Type: GrantFiled: March 18, 2004Date of Patent: January 5, 2010Assignee: Schering CorporationInventors: Bandarpalle B. Shankar, Razia K. Rizvi, Joseph A. Kozlowski, Neng-Yang Shih
-
Patent number: 7632523Abstract: An enhanced activity aqueous disinfecting solution having a pH of from about 0.5 to about 6 and consisting essentially of (i) hydrogen peroxide in a concentration of from about 0.Type: GrantFiled: September 11, 2006Date of Patent: December 15, 2009Assignee: Virox Technologies Inc.Inventors: Jose A. Ramirez, Navid Omidbakhsh
-
Publication number: 20090306016Abstract: Disclosed are compounds of formula R—X—Y that may be used to inhibit the action of fatty acid amide hydrolase (FAAH). Inhibition of fatty acid amide hydrolase (FAAH) will slow the normal degradation and inactivation of endogenous cannabinoid ligands by FAAH hydrolysis and allow higher levels of those endogenous cannabinergic ligands to remain present. These higher levels of endocannabinoid ligands provide increased stimulation of the cannabinoid CB1i and CB2 receptors and produce physiological effects related to the activation of the cannabinoid receptors. They will also enhance the effects of other exogenous cannabinergic ligands and allow them to produce their effects at lower concentrations as compared to systems in which fatty acid amide hydrolase (FAAH) action is hot inhibited. Thus, a compound that inhibits the inactivation of endogenous cannabinoid ligands by fatty acid amide hydrolase (FAAH) may increase the levels of endocannabinoids and, thus, enhance the activation of cannabinoid receptors.Type: ApplicationFiled: July 27, 2007Publication date: December 10, 2009Inventors: Alexandros Makriyannis, Spyridon P. Nikas, Shakiru O. Alapafuja, Vidyanand G. Shukla
-
Patent number: 7595347Abstract: Pre-treatment with ?,? unsaturated aryl sulfones protects normal cells from the cytotoxic side effects of two classes of anticancer chemotherapeutics. Administration of a cytoprotective sulfone compound to a patient prior to anticancer chemotherapy with a mitotic phase cell cycle inhibitor or topoisomerase inhibitor reduces or eliminates the cytotoxic side effects of the anticancer agent on normal cells. The cytoprotective effect of the ?,? unsaturated aryl sulfone allows the clinician to safely increasing the dosage of the anticancer chemotherapeutic.Type: GrantFiled: May 21, 2004Date of Patent: September 29, 2009Assignee: Temple University—Of The Commonwealth System of Higher EducationInventors: Stephen C. Cosenza, M. V. Ramana Reddy, E. Premkumar Reddy
-
Patent number: 7589056Abstract: Use of a polylysine, polyamidoamine or polypropylenimine dendrimer having naphthyl disulphonate terminal groups as a topically applied agent in prophylaxis or treatment of sexually transmitted diseases.Type: GrantFiled: March 28, 2002Date of Patent: September 15, 2009Assignee: Starpharma Pty. Ltd.Inventors: Barry Ross Matthews, George Holan, Peter Karellas, Scott Andrew Henderson, David Francis O'Keefe
-
Patent number: 7585887Abstract: The invention relates to novel active compound combinations having very good insecticidal and acaricidal properties and containing (a) cyclic ketoenols having the formula ?in which the groups W, X, Y, Z, A, B, D, and G have the meanings given in the disclosure, and (b) the active compounds (1) to (29) listed in the disclosure.Type: GrantFiled: October 29, 2001Date of Patent: September 8, 2009Assignee: Bayer CropScience AGInventors: Reiner Fischer, Christoph Erdelen
-
Publication number: 20090170824Abstract: Compounds of formula I: are potent and selective antagonists of the human 5-HT2A receptor, and hence useful in treatment of a variety of adverse conditions of the CNS.Type: ApplicationFiled: December 12, 2008Publication date: July 2, 2009Inventors: Jose Luis Castro Pineiro, Laura Catherine Cooper, Myra Gilligan, Alexander Charles Humphries, Peter Alen Hunt, Tamara Ladduwahetty, Angus Murray MacLeod, Kevin John Merchant, Monique Bodil Van Niel, Kevin Wilson
-
Publication number: 20090149510Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase cascade.Type: ApplicationFiled: July 7, 2008Publication date: June 11, 2009Inventor: David G. Hangauer, JR.
-
Publication number: 20090143334Abstract: A method of protecting wood through enhanced penetration of wood preservatives includes providing a solution including (a) at least one amine oxide. (b) at least one organic wood preservative and (c) a buffering agent. The solution preferably has a pH of about 7 to 10. The solution is applied to the surface of the wood after which, with or without intervening storage, the materials are activated to effect enhanced penetration of the organic wood preservative into the wood. One may effect application at a solution temperature of about 30 to 75° C. and preferably about 50 to 60° C. to effect activation at a higher temperature and high relative humidity. In a preferred practice, the wood may be heated before and/or after application of the solution. The solution is also disclosed as a product.Type: ApplicationFiled: February 5, 2009Publication date: June 4, 2009Inventors: Hans A. Ward, Cameron Scott
-
Publication number: 20090131536Abstract: The present invention features methods of treating renal cancer by administration of certain dimethylsulfonate compounds. The present invention further features administration protocols and dosing schedules for methods of treating patients suffering from renal cancer and pharmaceutical compositions suitable for use in the treatment methods provided herein.Type: ApplicationFiled: October 14, 2005Publication date: May 21, 2009Applicant: GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Susan D. Mertins, Susan E. Bates, David G. Covell, Geoffrey W. Patton, Melinda G. Hollingshead, Rao Vishnuvajjalla
-
Publication number: 20090131419Abstract: Disclosed are sulphones which modulate the action of gamma-secretase. The compounds are useful in the treatment or prevention of Alzheimer's disease.Type: ApplicationFiled: May 6, 2008Publication date: May 21, 2009Inventors: Jose Luis Castro Pineiro, Ian Churcher, Kevin Dinnell, Timothy Harrison, Sonia Kerrad, Alan John Nadin, Paul Joseph Oakley, Andrew Pate Owens, Duncan Edward Shaw, Martin Richard Teall, Susannah William, Brian John Williams
-
Patent number: 7517901Abstract: Compounds of formula Ia or Ib: wherein X and Y are nitrogen or CRe, and R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the subject compounds and methods of using the compounds for treatment of p38-mediated diseases.Type: GrantFiled: August 23, 2006Date of Patent: April 14, 2009Assignee: Roche Palo Alto LLCInventors: Tobias Gabriel, Michael Soth
-
Patent number: RE41279Abstract: The mastitis control teat dip composition having a visible indicator aspect of the invention provides a softening, soothing, smoothing, relaxing property, a rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The indicator aspect provides ease of visually detecting the material on the animal skin and can indicate efficacy of the material. The compositions of the invention are made by combining an aqueous liquid composition containing the visual indicator combined with the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite.Type: GrantFiled: March 2, 2006Date of Patent: April 27, 2010Assignee: Ecolab Inc.Inventors: David D. McSherry, Francis L. Richter